Dornase alpha and exhaled NO in cystic fibrosis

Pediatric Pulmonology
H GrasemannAndrew A Colin

Abstract

Nitric oxide (NO) that is produced within the airways can be measured in the exhaled air. Concentrations of exhaled NO (FENO) are decreased in cystic fibrosis (CF) and, in cross sectional studies, have been shown to be even lower in patients with more advanced pulmonary disease. This may result from retention and metabolisation of NO within viscous airway secretions. Treatment with recombinant human DNase I (dornase alpha) modifies the rheological properties of airway secretions and thereby improves pulmonary function even in young and apparently healthy patients with CF. We studied FENO and pulmonary function in children with CF with little clinical evidence of lung morbidity in a two-year randomized double-blind placebo-controlled study with nebulized dornase alpha. Mean age at enrollment was 8 years (range 6 to 11 years), mean forced vital capacity (FVC) was 112% (range 86 to 133%), and mean forced expiratory volume in one second (FEV1)was 109% (range 88 to 128%) of predicted values. In five of six (83%) of the dornase alpha treated patients, FENO changed in parallel to changes in pulmonary function tests while no such correlation was observed in any of the eight patients receiving placebo. This difference between treatment ...Continue Reading

References

Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S ShakC L Baker
Dec 18, 1993·Lancet·Q HamidJ M Polak
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·K AsanoJ S Stamler
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·F H GuoS C Erzurum
Aug 1, 1995·American Journal of Respiratory and Critical Care Medicine·A F MassaroJ M Drazen
Oct 1, 1993·Thorax·P J Barnes, M G Belvisi
Feb 1, 1993·Pediatric Pulmonology·X WangB G Ferris
Aug 12, 1997·Biochemistry·K DavoodianM R Bubb
Apr 16, 1998·Archives of Disease in Childhood·H GrasemannF Ratjen
Jul 9, 1998·American Journal of Respiratory and Critical Care Medicine·S J LinnaneP McLoughlin
Oct 6, 1999·American Journal of Respiratory and Critical Care Medicine·H BisgaardJ A Oj
Dec 10, 1999·Pediatric Pulmonology·H Grasemann, F Ratjen
Aug 5, 2000·Allergy·G U Di MariaG Mazzarella
Aug 9, 2001·The European Respiratory Journal·S J LinnaneM X FitzGerald
Dec 18, 2001·The Journal of Pediatrics·J M QuanUNKNOWN Pulmozyme Early Intervention Trial Study Group
Jan 31, 2002·American Journal of Respiratory and Critical Care Medicine·Benjamin GastonJoanna B Goldberg
Jun 19, 2002·American Journal of Respiratory and Critical Care Medicine·Aaron DeykinElliot Israel
Aug 3, 2002·American Journal of Respiratory and Critical Care Medicine·Ranjan SuriJanis K Shute
Aug 9, 2002·The European Respiratory Journal·E BaraldiUNKNOWN European Respiratory Society/American Thoracic Society (ERS/ATS) Task Force
Sep 18, 2002·Archives of Biochemistry and Biophysics·Brian M MorrisseyDavid M Rodman
Dec 20, 2003·American Journal of Respiratory and Critical Care Medicine·Karl PaulUNKNOWN Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group
Mar 17, 2004·Pediatric Pulmonology·Jamie L WooldridgeFrank J Accurso
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Adam JafféAidan Laverty

❮ Previous
Next ❯

Citations

Oct 13, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Rainer Büscher, Hartmut Grasemann
Apr 22, 2006·American Journal of Respiratory and Critical Care Medicine·Hartmut GrasemannFelix Ratjen
Sep 1, 2007·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Cystic Fibrosis Foundation, Pulmonary Therapies Committee
Jul 27, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Kavitha KothaJohn P Clancy
Mar 18, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Raj PadmanIan Nathanson
Jun 29, 2005·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Karin M de Winter-de Groot, Cornelis K van der Ent
Jun 1, 2008·Expert Review of Respiratory Medicine·Clement L Ren
Jul 28, 2016·The Cochrane Database of Systematic Reviews·Ruth Dentice, Mark Elkins
Sep 7, 2018·The Cochrane Database of Systematic Reviews·Connie Yang, Mark Montgomery
Nov 28, 2018·The Cochrane Database of Systematic Reviews·Ruth Dentice, Mark Elkins
Dec 18, 2015·European Clinical Respiratory Journal·Andrei MalinovschiZuzana Diamant
Apr 5, 2016·The Cochrane Database of Systematic Reviews·Connie YangSarah J Nolan
Jan 4, 2017·Expert Opinion on Orphan Drugs·Elizabeth L Kramer, John P Clancy
Mar 10, 2021·The Cochrane Database of Systematic Reviews·Ruth Dentice, Mark Elkins
Mar 19, 2021·The Cochrane Database of Systematic Reviews·Connie Yang, Mark Montgomery

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Respiratory and Critical Care Medicine
Karl PaulBronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Maartje Ten BergeJ C de Jongste
© 2021 Meta ULC. All rights reserved